Skip to content

Welcome to Discover Pharma! Today is : October 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 2 trial

  • Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    Al-S Pharma presents Phase 2 AP-101 data supporting misfolded SOD1 target in ALS at ENCALS 2026

    Al-S Pharma reports Phase 2 AP-101 data in ALS showing [...]

    June 25, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Phase 2 trial begins for fetal growth restriction therapy with no approved drug treatments available

    The first patients have been dosed in a Phase 2 [...]

    June 24, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Oral GLP-1 candidate CX11 achieves 11.5% weight loss in US Phase 2 obesity trial

    CORXEL Pharmaceuticals reported positive Phase 2 results for oral GLP-1 [...]

    June 24, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Gesynta reaches halfway point in Phase 2 endometriosis trial

    Gesynta Pharma has randomised half of the planned patients in [...]

    June 18, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy

    Elicio Therapeutics has reported that its Phase 2 Amplify-7P trial [...]

    June 15, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Protara reports durable 12-month responses for TARA-002 in Phase 2 bladder cancer trial

    Protara Therapeutics has reported updated 12-month data from its ongoing [...]

    May 19, 2026
  • Clinical & Regulatory,Therapeutic Areas

    Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial

    Kainova Therapeutics has dosed the first patient in Europe in [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    Levicept reports Phase 2 osteoarthritis data in The Lancet showing pain reduction with LEVI-04

    Levicept has reported Phase 2 clinical trial results for LEVI-04 [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    SolasCure phase 2 trial shows faster healing in venous leg ulcers

    SolasCure has reported positive phase 2 data for Aurase Wound [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Sensei acquires Faeth and secures $200M to advance PIKTOR in endometrial and breast cancer

    Sensei Biotherapeutics has acquired Faeth Therapeutics and announced a concurrent [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SurVaxM improves survival in Phase 2b glioblastoma trial
    Categories: Central Nervous System, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Lab-grown human neuromuscular junctions advance MND drug discovery
    Categories: Research & Development, Therapeutic Areas
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top